The FDA is requiring a new warning on all GLP-1 drugs about non-arteritic anterior ischemic optic neuropathy (NAION), which it says can cause permanent vision loss, citing an analysis of more than 125 trials that found about 6 cases per 100,000 patients on a GLP-1 for at least a year versus under 4 per 100,000 on placebo or other glucose-lowering drugs. MPR News
MPR NewsFDA adds rare vision-loss warning to popular GLP-1 drugsPopular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday.
How should a rare risk like this be weighed against the benefits of these drugs in labeling?
Micwyn· CultureAI moved this conversation to GLP-1 Drugs . Reason: Filed into a square started automatically for this tag.
· details or appeal